These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 32658625)

  • 1. Exploring the status and views of managed entry agreements in Saudi Arabia: mixed-methods approach.
    Al-Omar HA; Alghannam HH; Aljuffali IA
    Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):837-845. PubMed ID: 32658625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Managed Entry Agreements: Policy Analysis From the European Perspective.
    Dabbous M; Chachoua L; Caban A; Toumi M
    Value Health; 2020 Apr; 23(4):425-433. PubMed ID: 32327159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Managed Entry Agreements for Pharmaceutical Products in Middle East and North African Countries: Payer and Manufacturer Experience and Outlook.
    Maskineh C; Nasser SC
    Value Health Reg Issues; 2018 Sep; 16():33-38. PubMed ID: 29936067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications.
    Ferrario A; Arāja D; Bochenek T; Čatić T; Dankó D; Dimitrova M; Fürst J; Greičiūtė-Kuprijanov I; Hoxha I; Jakupi A; Laidmäe E; Löblová O; Mardare I; Markovic-Pekovic V; Meshkov D; Novakovic T; Petrova G; Pomorski M; Tomek D; Voncina L; Haycox A; Kanavos P; Vella Bonanno P; Godman B
    Pharmacoeconomics; 2017 Dec; 35(12):1271-1285. PubMed ID: 28836222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationalizing the introduction and use of pharmaceutical products: The role of managed entry agreements in Central and Eastern European countries.
    Rotar AM; Preda A; Löblová O; Benkovic V; Zawodnik S; Gulacsi L; Niewada M; Boncz I; Petrova G; Dimitrova M; Klazinga N
    Health Policy; 2018 Mar; 122(3):230-236. PubMed ID: 29373186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis.
    Vreman RA; Broekhoff TF; Leufkens HG; Mantel-Teeuwisse AK; Goettsch WG
    Int J Environ Res Public Health; 2020 Nov; 17(22):. PubMed ID: 33182732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CHARACTERISTICS OF MANAGED ENTRY AGREEMENTS IN AUSTRALIA.
    Robinson MF; Mihalopoulos C; Merlin T; Roughead E
    Int J Technol Assess Health Care; 2018 Jan; 34(1):46-55. PubMed ID: 29277174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stakeholder Insights into Czech Performance-Based Managed Entry Agreements: Potential for Transformative Change in Pharmaceutical Access?
    Hospodková P; Karásek P; Tichopád A
    Healthcare (Basel); 2024 Jan; 12(1):. PubMed ID: 38201024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stakeholder views of managed entry agreements: A literature review of national studies.
    Thanimalai S; Choon WY; Lee KK
    Health Policy Open; 2021 Dec; 2():100032. PubMed ID: 37383516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Innovative pharmaceutical pricing agreements in five European markets: A survey of stakeholder attitudes and experience.
    Dunlop WCN; Staufer A; Levy P; Edwards GJ
    Health Policy; 2018 May; 122(5):528-532. PubMed ID: 29567205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A MEA is a MEA is a MEA? Sequential decision making and the impact of different managed entry agreements at the manufacturer and payer level, using a case study for an oncology drug in England.
    Buyukkaramikli NC; Wigfield P; Hoang MT
    Eur J Health Econ; 2021 Feb; 22(1):51-73. PubMed ID: 32901420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How Do Iranian Stakeholders Think About Pharmaceutical Managed Entry Agreements?
    Shobeiri N; Peiravian F; Yousefi N
    Iran J Pharm Res; 2022 Dec; 21(1):e126916. PubMed ID: 36060922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Financial Outcomes of Managed Entry Agreements for Pharmaceuticals in Italy.
    Trotta F; Guerrizio MA; Di Filippo A; Cangini A
    JAMA Health Forum; 2023 Dec; 4(12):e234611. PubMed ID: 38153808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medicine price transparency and confidential managed-entry agreements in Europe: findings from the EURIPID survey.
    Russo P; Carletto A; Németh G; Habl C
    Health Policy; 2021 Sep; 125(9):1140-1145. PubMed ID: 34253396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of managed entry agreements on pharmaceutical prices.
    Gamba S; Pertile P; Vogler S
    Health Econ; 2020 Oct; 29 Suppl 1():47-62. PubMed ID: 32628324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The current performance-linked and risk sharing agreement scene in the Spanish region of Catalonia.
    Darbà J; Ascanio M
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):743-748. PubMed ID: 30821532
    [No Abstract]   [Full Text] [Related]  

  • 17. Utilisation of hospital information systems for medical research in Saudi Arabia: A mixed-method exploration of the views of healthcare and IT professionals involved in hospital database management systems.
    Samra H; Li A; Soh B; Zain MA
    Health Inf Manag; 2020; 49(2-3):117-126. PubMed ID: 31046465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Managed Entry Agreements on availability of and timely access to medicines: an ex-post evaluation of agreements implemented for oncology therapies in four countries.
    Efthymiadou O; Kanavos P
    BMC Health Serv Res; 2022 Aug; 22(1):1066. PubMed ID: 35987627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries.
    Morel T; Arickx F; Befrits G; Siviero P; van der Meijden C; Xoxi E; Simoens S
    Orphanet J Rare Dis; 2013 Dec; 8():198. PubMed ID: 24365263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden.
    Ferrario A; Kanavos P
    Soc Sci Med; 2015 Jan; 124():39-47. PubMed ID: 25461860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.